SG11201907448RA - Macrocyclic broad spectrum antibiotics - Google Patents
Macrocyclic broad spectrum antibioticsInfo
- Publication number
- SG11201907448RA SG11201907448RA SG11201907448RA SG11201907448RA SG11201907448RA SG 11201907448R A SG11201907448R A SG 11201907448RA SG 11201907448R A SG11201907448R A SG 11201907448RA SG 11201907448R A SG11201907448R A SG 11201907448RA SG 11201907448R A SG11201907448R A SG 11201907448RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- road
- san
- compounds
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title abstract 2
- 229940088710 antibiotic agent Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 241000208140 Acer Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 240000005020 Acaciella glauca Species 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 244000187664 Nerium oleander Species 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 235000003499 redwood Nutrition 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 108010087967 type I signal peptidase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2017/073575 | 2017-02-15 | ||
| CNPCT/CN2017/085075 | 2017-05-19 | ||
| PCT/CN2018/076957 WO2018149419A1 (en) | 2017-02-15 | 2018-02-22 | Macrocyclic broad spectrum antibiotics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907448RA true SG11201907448RA (en) | 2019-09-27 |
Family
ID=63169158
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907448RA SG11201907448RA (en) | 2017-02-15 | 2018-02-22 | Macrocyclic broad spectrum antibiotics |
| SG10202108876TA SG10202108876TA (en) | 2017-02-15 | 2018-02-22 | Macrocyclic broad spectrum antibiotics |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202108876TA SG10202108876TA (en) | 2017-02-15 | 2018-02-22 | Macrocyclic broad spectrum antibiotics |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20210198316A9 (enExample) |
| EP (2) | EP4371982A3 (enExample) |
| JP (2) | JP7134177B2 (enExample) |
| KR (1) | KR102671585B1 (enExample) |
| CN (1) | CN110520413B (enExample) |
| AU (2) | AU2018222093B2 (enExample) |
| BR (1) | BR112019017003A2 (enExample) |
| CL (1) | CL2019002305A1 (enExample) |
| CO (1) | CO2019010001A2 (enExample) |
| CR (2) | CR20210144A (enExample) |
| ES (1) | ES2979245T3 (enExample) |
| IL (1) | IL268483B2 (enExample) |
| MA (1) | MA47514A (enExample) |
| MX (2) | MX2019009752A (enExample) |
| MY (1) | MY199461A (enExample) |
| PE (2) | PE20191618A1 (enExample) |
| PH (1) | PH12019501904A1 (enExample) |
| SG (2) | SG11201907448RA (enExample) |
| UA (1) | UA126027C2 (enExample) |
| WO (1) | WO2018149419A1 (enExample) |
| ZA (1) | ZA201905371B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180109858A (ko) | 2015-11-20 | 2018-10-08 | 알큐엑스 파마슈티컬스, 인크. | 마크로시클릭 광범위 항생제 |
| IL265389B1 (en) | 2016-09-16 | 2026-07-01 | Quince Therapeutics Inc | Ketone compounds lysine inhibitors gingerapine, preparations containing them and uses thereof |
| IL288294B (en) | 2019-05-28 | 2022-09-01 | Hoffmann La Roche | A broad-spectrum macrocyclic antibiotic |
| CN112480007B (zh) * | 2020-12-08 | 2022-11-18 | 宿迁市科莱博生物化学有限公司 | 一种1，3-二甲基-1h-吡唑-4-羧酸的合成方法 |
| EP4284804A1 (en) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| CN116284026B (zh) * | 2023-03-16 | 2024-05-14 | 天津师范大学 | 一种水溶性阳离子分子笼及其合成方法与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102939095A (zh) * | 2010-03-09 | 2013-02-20 | 默沙东公司 | 增强β-内酰胺抗菌药物的活性的桥联脂糖肽类 |
| MX2013003035A (es) * | 2010-09-15 | 2013-12-16 | Scripps Research Inst | Analogos de arilomicina como antibióticos de amplio espectro. |
| WO2012166665A2 (en) * | 2011-05-27 | 2012-12-06 | Rqx Pharmaceuticals, Inc. | Broad spectrum antibiotics |
| KR20140140580A (ko) * | 2012-03-14 | 2014-12-09 | 더 스크립스 리서치 인스티튜트 | 광범위 항생제 아릴로마이신 유사체 |
| CN104620391B (zh) * | 2012-10-23 | 2017-09-19 | 富士电机株式会社 | 半导体装置及其制造方法 |
| CN103788176A (zh) * | 2012-10-31 | 2014-05-14 | 上海来益生物药物研究开发中心有限责任公司 | 一种arylomycin类化合物及其制备方法和应用 |
| CA2892027A1 (en) * | 2012-11-21 | 2014-05-30 | Rqx Pharmaceuticals, Inc. | Macrocyclic broad spectrum antibiotics |
| US20190067498A1 (en) * | 2017-08-28 | 2019-02-28 | Meng Tao | Light-induced aluminum plating on silicon for solar cell metallization |
| KR20170027721A (ko) * | 2014-05-20 | 2017-03-10 | 알큐엑스 파마슈티컬스, 인크. | 마크로시클릭 광범위 항생제 |
| KR20180109858A (ko) * | 2015-11-20 | 2018-10-08 | 알큐엑스 파마슈티컬스, 인크. | 마크로시클릭 광범위 항생제 |
| TWI725075B (zh) * | 2015-11-20 | 2021-04-21 | 美商Ｒｑｘ製藥公司 | 巨環廣效抗生素 |
| MX386696B (es) | 2017-03-27 | 2025-03-19 | Hoffmann La Roche | Proceso para producir analogos de anillo de arilomicina |
-
2018
- 2018-02-22 UA UAA201909231A patent/UA126027C2/uk unknown
- 2018-02-22 MX MX2019009752A patent/MX2019009752A/es unknown
- 2018-02-22 PE PE2019001675A patent/PE20191618A1/es unknown
- 2018-02-22 AU AU2018222093A patent/AU2018222093B2/en active Active
- 2018-02-22 MY MYPI2019004670A patent/MY199461A/en unknown
- 2018-02-22 CR CR20210144A patent/CR20210144A/es unknown
- 2018-02-22 MA MA047514A patent/MA47514A/fr unknown
- 2018-02-22 SG SG11201907448RA patent/SG11201907448RA/en unknown
- 2018-02-22 ES ES18754727T patent/ES2979245T3/es active Active
- 2018-02-22 BR BR112019017003A patent/BR112019017003A2/pt not_active Application Discontinuation
- 2018-02-22 CN CN201880025278.0A patent/CN110520413B/zh active Active
- 2018-02-22 KR KR1020197026779A patent/KR102671585B1/ko active Active
- 2018-02-22 EP EP24161427.0A patent/EP4371982A3/en active Pending
- 2018-02-22 EP EP18754727.8A patent/EP3583096B1/en active Active
- 2018-02-22 PE PE2024002053A patent/PE20242298A1/es unknown
- 2018-02-22 JP JP2019542369A patent/JP7134177B2/ja active Active
- 2018-02-22 CR CR20190428A patent/CR20190428A/es unknown
- 2018-02-22 SG SG10202108876TA patent/SG10202108876TA/en unknown
- 2018-02-22 WO PCT/CN2018/076957 patent/WO2018149419A1/en not_active Ceased
- 2018-02-22 IL IL268483A patent/IL268483B2/en unknown
-
2019
- 2019-08-13 US US16/539,947 patent/US20210198316A9/en not_active Abandoned
- 2019-08-14 MX MX2022014485A patent/MX2022014485A/es unknown
- 2019-08-14 CL CL2019002305A patent/CL2019002305A1/es unknown
- 2019-08-14 ZA ZA2019/05371A patent/ZA201905371B/en unknown
- 2019-08-15 PH PH12019501904A patent/PH12019501904A1/en unknown
- 2019-09-13 CO CONC2019/0010001A patent/CO2019010001A2/es unknown
-
2022
- 2022-03-11 AU AU2022201724A patent/AU2022201724B9/en active Active
- 2022-08-30 JP JP2022137159A patent/JP7461425B2/ja active Active
- 2022-10-18 US US18/047,624 patent/US20230133667A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201900482SA (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201809229VA (en) | Pharmaceutical composition | |
| SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201807720TA (en) | Methods and systems for determining antibiotic susceptibility | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201907153RA (en) | Topical formulations and methods | |
| SG11201909840TA (en) | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |